Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics has secured a £40 million loan facility from Hayfin Capital Management and increased its existing shareholder facility to £50 million, providing substantial capital to drive its business forward. This strategic move is expected to enhance the company’s manufacturing capacity and support its growth in sales. The funding positions Allergy Therapeutics favorably for future growth in the allergy treatment sector.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
